MARKET

XENE

XENE

Xenon Pharmaceut
NASDAQ
62.35
-1.88
-2.93%
After Hours: 62.55 +0.2 +0.32% 19:34 08/14 EDT
OPEN
63.60
PREV CLOSE
64.23
HIGH
63.90
LOW
61.63
VOLUME
921.88K
TURNOVER
--
52 WEEK HIGH
72.66
52 WEEK LOW
32.78
MARKET CAP
6.04B
P/E (TTM)
-13.1440
1D
5D
1M
3M
1Y
5Y
1D
Xenon Insider Makes a Big Move With High-Value Stock Sale
TipRanks · 2d ago
Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript
NASDAQ · 2d ago
Xenon (XENE) Gets a Buy from Stifel Nicolaus
TipRanks · 3d ago
Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity
Seeking Alpha · 5d ago
J.P. Morgan Remains a Buy on Xenon (XENE)
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Relay Therapeutics (RLAY) and Amylyx Pharmaceuticals Inc (AMLX)
TipRanks · 6d ago
Weekly Report: what happened at XENE last week (0803-0807)?
Weekly Report · 6d ago
Xenon Therapeutics: Buy Rating Reiterated as AZK Progress and Strong Cash Position Support Compelling Risk-Reward; Price Target Maintained at $78
TipRanks · 08/07 22:55
More
About XENE
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.

Webull offers Xenon Pharmaceuticals Inc stock information, including NASDAQ: XENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XENE stock methods without spending real money on the virtual paper trading platform.